News

Topical Ciprofloxacin/Dexamethasone Good for AOM With Otorrhea


 

LOS ANGELES — Topical ciprofloxacin/dexamethasone is effective in treating acute otitis media with otorrhea through tympanostomy tubes, Dr. Joseph E. Dohar wrote in a poster presentation at the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery Foundation.

Topical ciprofloxacin 0.3% and dexamethasone 0.1%, marketed as Ciprodex sterile otic suspension, produced more clinical cures, earlier cessation of otorrhea, and caused fewer side effects than oral amoxicillin/clavulanate potassium (Augmentin), wrote Dr. Dohar, an otolaryngologist at the Children's Hospital of Pittsburgh. Alcon Laboratories, maker of Ciprodex, sponsored the study.

Dr. Dohar is a clinical investigator, consultant, and speaker for the company.

“My personal experience has been extremely favorable when using topical ciprofloxacin/dexamethasone,” Dr. Dohar said in an interview.

“The topical combination is superior to systemic antibiotics, due to better cure rates, more effective killing of bacteria, less treatment-related resistance, and far fewer side effects.”

In this observer-masked, prospective multicenter trial, 80 children aged 6 months to 8 years (mean 2 years) with acute otitis media and otorrhea were randomized to treatment with either topical ciprofloxacin/dexamethasone drops or a 5-mL oral suspension of 600 mg amoxicillin/42.9 mg clavulanate potassium.

The median time to cessation of otorrhea was 4 days in the ciprofloxacin/dexamethasone group and 7 days in the amoxicillin/clavulanic acid group.

Ciprofloxacin/dexamethasone also had fewer side effects.

Of the children receiving the drops, 5% complained of ear pain, compared with 20% of children taking the suspension had diarrhea.

The treatment failure rate was 17% for ciprofloxacin/dexamethasone and 41% for amoxicillin/clavulanic acid.

These results are impressive, Dr. Dohar said in an interview.

“The study design was meticulous, and a relatively small sample size resulted in such a positive outcome. It is rare in the modern era of anti-infectives to be able to demonstrate superiority.”

Recommended Reading

Tamiflu Prophylaxis Expands Down to Age 1
MDedge Pediatrics
Today's Rapid Strep Tests May Obviate Backup Cultures
MDedge Pediatrics
Imported Congenital Rubella Syndrome Case Seen in N.H.
MDedge Pediatrics
All-Time Low in Measles Cases Reported in 2004
MDedge Pediatrics
New C. difficile Strains Traced to Antibiotic Use : Fluoroquinolone use may be involved in the development of the newer, more virulent strains.
MDedge Pediatrics
Pneumococcal Parapneumonic Empyema Up in Some Areas
MDedge Pediatrics
Young Patient Age Is a New C. difficile Risk Factor
MDedge Pediatrics
West Nile Incidence on the Rise, CDC Reports
MDedge Pediatrics
Oral Nystatin Cuts Neonatal Candida Risk
MDedge Pediatrics
Pediatric Myositis, Pyomyositis May Be Increasing
MDedge Pediatrics